{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:21:51Z","timestamp":1793830911659,"version":"4.6.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Orthop Surg Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Osteoarthritis (OA) is a widespread joint disease characterized by the gradual loss of cartilage. Intra-articular injections, including platelet-rich plasma (PRP), are commonly used for treatment, but the optimal PRP preparation method remains debated. This study aims to perform a network meta-analysis of randomized controlled trials to compare the efficacy of different PRP preparation methods and determine the most effective protocols.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The literature search was conducted based on PRISMA guidelines. Randomized controlled trials (RCTs) evaluating intra-articular injectables in osteoarthritic knees were included. Data were extracted, and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores were analyzed at 3, 6, and 12\u201318 months. Clinical outcomes were compared using a frequentist network meta-analysis, and treatment options were ranked using the P-Score. Statistical analysis was performed using R 4.3.2.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Twenty-three RCTs with 1752 patients were included. Treatments included PRP, plasma rich in growth factor (PRGF), leukocyte-poor PRP (LP-PRP), leukocyte-rich PRP (LR-PRP), hyaluronic acid (HA), and saline placebo. Leukocyte-rich PRP with low platelet concentration increase, using both anticoagulant and activator showed the best effects on WOMAC pain and stiffness scores within 6 months (WMD\u2009=\u200926.02; 95% CrI, 0.92\u201352.46). Leukocyte-poor PRP with high platelet concentration increase, using anticoagulant without activator was most effective for WOMAC function and stiffness at 12\u201318 months (WMD\u2009=\u200918.94; 95% CrI, 8.34\u201328.12). Long-term results indicated Leukocyte-poor PRP with low platelet concentration increase, using anticoagulant without activator yielded the best outcomes for cartilage repair and function (WMD\u2009=\u200917.09; 95% CrI, -8.4 to 42.78).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Optimizing OA treatment involves tailoring PRP protocols to disease stage, with low platelet, high leukocyte PRP (RPRP_LPC_Y_Y) recommended for early OA due to its anti-inflammatory effects and high platelet, low leukocyte PRP (PPRP-HPC) preferred for advanced OA to promote tissue repair and regeneration.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13018-025-06026-1","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T02:46:46Z","timestamp":1750733206000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The efficacy of platelet-rich plasma preparation protocols in the treatment of osteoarthritis: a network meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"20","author":[{"given":"Dongsheng","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiani","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"issue":"6","key":"6026_CR1","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2217\/rme-2018-0042","volume":"13","author":"I Andia","year":"2018","unstructured":"Andia I, Maffulli N. A contemporary view of platelet-rich plasma therapies: moving toward refined clinical protocols and precise indications. Regen Med. 2018;13(6):717\u201328. https:\/\/doi.org\/10.2217\/rme-2018-0042.","journal-title":"Regen Med"},{"issue":"18","key":"6026_CR2","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.3390\/ijms20184581","volume":"20","author":"I Andia","year":"2019","unstructured":"Andia I, Maffulli N. Blood-Derived products for tissue repair\/regeneration. Int J Mol Sci. 2019;20(18):4581. https:\/\/doi.org\/10.3390\/ijms20184581. Published 2019 Sep 17.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"6026_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10195-018-0505-z","volume":"19","author":"I Andia","year":"2018","unstructured":"Andia I, Maffulli N. Some patients (and some of us) respond better to some biological therapies: the as yet unsolved conundrum. J Orthop Traumatol. 2018;19(1):1. https:\/\/doi.org\/10.1186\/s10195-018-0505-z. Published 2018 Aug 20.","journal-title":"J Orthop Traumatol"},{"issue":"8","key":"6026_CR4","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1517\/14712598.2013.801450","volume":"13","author":"E Anitua","year":"2013","unstructured":"Anitua E, S\u00e1nchez M, Orive G, Padilla S. A biological therapy to osteoarthritis treatment using platelet-rich plasma. Expert Opin Biol Ther. 2013;13(8):1161\u201372. https:\/\/doi.org\/10.1517\/14712598.2013.801450.","journal-title":"Expert Opin Biol Ther"},{"key":"6026_CR5","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s40265-023-01863-y","volume":"83","author":"R Assi","year":"2023","unstructured":"Assi R, Quintiens J, Monteagudo S, et al. Innovation in targeted intra-articular therapies for osteoarthritis. Drugs. 2023;83:649\u201363. https:\/\/doi.org\/10.1007\/s40265-023-01863-y.","journal-title":"Drugs"},{"issue":"1","key":"6026_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.7326\/m14-1231","volume":"162","author":"RR Bannuru","year":"2015","unstructured":"Bannuru RR, Schmid CH, Kent DM, et al. Comparative effectiveness of Pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 2015;162(1):46\u201354. https:\/\/doi.org\/10.7326\/m14-1231.","journal-title":"Ann Intern Med"},{"key":"6026_CR7","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1038\/s41598-021-83025-2","volume":"11","author":"H Bansal","year":"2021","unstructured":"Bansal H, Leon J, Pont JL, et al. Platelet-rich plasma (PRP) in osteoarthritis (OA) knee: correct dose critical for long-term clinical efficacy. Sci Rep. 2021;11:3971. https:\/\/doi.org\/10.1038\/s41598-021-83025-2.","journal-title":"Sci Rep"},{"issue":"1","key":"6026_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/230949901502300102","volume":"23","author":"P Behera","year":"2015","unstructured":"Behera P, Dhillon M, Aggarwal S, Marwaha N, Prakash M. Leukocyte-poor platelet-rich plasma versus bupivacaine for recalcitrant lateral epicondylar tendinopathy. J Orthop Surg (Hong Kong). 2015;23(1):6\u201310.","journal-title":"J Orthop Surg (Hong Kong)"},{"issue":"1","key":"6026_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/0363546513490656","volume":"42","author":"SG Boswell","year":"2014","unstructured":"Boswell SG, Schnabel LV, Mohammed HO, et al. Increasing platelet concentrations in leukocyte-reduced platelet-rich plasma decrease collagen gene synthesis in tendons. Am J Sports Med. 2014;42(1):42\u20139. https:\/\/doi.org\/10.1177\/0363546513490656.","journal-title":"Am J Sports Med"},{"issue":"1","key":"6026_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s10195-018-0501-3","volume":"19","author":"D Buend\u00eda-L\u00f3pez","year":"2018","unstructured":"Buend\u00eda-L\u00f3pez D, Medina-Quir\u00f3s M, Fern\u00e1ndez-Villaca\u00f1as Mar\u00edn M\u00c1. Clinical and radiographic comparison of a single LP-PRP injection, a single hyaluronic acid injection and daily NSAID administration with a 52-week follow-up: a randomized controlled trial. J Orthop Traumatol. 2018;19(1):3. https:\/\/doi.org\/10.1186\/s10195-018-0501-3.","journal-title":"J Orthop Traumatol"},{"issue":"4","key":"6026_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/j.1582-4934.2005.tb00379.x","volume":"9","author":"AM Byrne","year":"2005","unstructured":"Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med. 2005;9(4):777\u201394.","journal-title":"J Cell Mol Med"},{"issue":"7","key":"6026_CR15","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.arthro.2012.04.148","volume":"28","author":"JM DeLong","year":"2012","unstructured":"DeLong JM, Russell RP, Mazzocca AD. Platelet-rich plasma: the PAW classification system. Arthroscopy. 2012;28(7):998\u20131009. https:\/\/doi.org\/10.1016\/j.arthro.2012.04.148.","journal-title":"Arthroscopy"},{"issue":"2","key":"6026_CR18","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00167-016-4110-5","volume":"25","author":"TM Duymus","year":"2017","unstructured":"Duymus TM, Mutlu S, Dernek B, et al. Choice of intra-articular injection in treatment of knee osteoarthritis: platelet-rich plasma, hyaluronic acid or Ozone options. Knee Surg Sports Traumatol Arthrosc. 2017;25(2):485\u201392. https:\/\/doi.org\/10.1007\/s00167-016-4110-5.","journal-title":"Knee Surg Sports Traumatol Arthrosc"},{"issue":"1","key":"6026_CR19","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1186\/s12891-021-04706-7","volume":"22","author":"M D\u00f3rio","year":"2021","unstructured":"D\u00f3rio M, Pereira RMR, Luz AGB, et al. Efficacy of platelet-rich plasma and plasma for symptomatic treatment of knee osteoarthritis: a double-blinded placebo-controlled randomized clinical trial. BMC Musculoskelet Disord. 2021;22(1):822. https:\/\/doi.org\/10.1186\/s12891-021-04706-7.","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"6026_CR20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3233\/BMR-181374","volume":"33","author":"H Elik","year":"2020","unstructured":"Elik H, Do\u011fu B, Y\u0131lmaz F, et al. The efficiency of platelet-rich plasma treatment in patients with knee osteoarthritis. J Back Musculoskelet Rehabil. 2020;33(1):127\u201338. https:\/\/doi.org\/10.3233\/BMR-181374.","journal-title":"J Back Musculoskelet Rehabil"},{"key":"6026_CR21","doi-asserted-by":"publisher","first-page":"7914","DOI":"10.3390\/ijms25147914","volume":"25","author":"PA Everts","year":"2024","unstructured":"Everts PA, Lana JF, Alexander RW, et al. Profound properties of protein-rich, platelet-rich plasma matrices as novel, multi-purpose biological platforms in tissue repair, regeneration, and wound healing. Int J Mol Sci. 2024;25:7914. https:\/\/doi.org\/10.3390\/ijms25147914.","journal-title":"Int J Mol Sci"},{"key":"6026_CR22","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.3390\/biomedicines11071922","volume":"11","author":"PA Everts","year":"2023","unstructured":"Everts PA, Lana JF, Onishi K, et al. Angiogenesis and tissue repair depend on platelet dosing and bioformulation strategies following orthobiological platelet-rich plasma procedures: a narrative review. Biomedicines. 2023;11:1922. https:\/\/doi.org\/10.3390\/biomedicines11071922.","journal-title":"Biomedicines"},{"key":"6026_CR23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/1471-2474-13-229","volume":"13","author":"G Filardo","year":"2012","unstructured":"Filardo G, Kon E, Di Martino A, et al. Platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: study design and preliminary results of a randomized controlled trial. BMC Musculoskelet Disord. 2012;13:229. https:\/\/doi.org\/10.1186\/1471-2474-13-229.","journal-title":"BMC Musculoskelet Disord"},{"issue":"9","key":"6026_CR24","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.3390\/biomedicines10092134","volume":"10","author":"A Gupta","year":"2022","unstructured":"Gupta A, Jeyaraman M, Maffulli N. Common medications which should be stopped prior to Platelet-Rich plasma injection. Biomedicines. 2022;10(9):2134. https:\/\/doi.org\/10.3390\/biomedicines10092134. Published 2022 Aug 31.","journal-title":"Biomedicines"},{"issue":"7414","key":"6026_CR25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"issue":"3","key":"6026_CR26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00132-018-03659-5","volume":"48","author":"Y Huang","year":"2019","unstructured":"Huang Y, Liu X, Xu X, et al. Intra-articular injections of platelet-rich plasma, hyaluronic acid or corticosteroids for knee osteoarthritis: a prospective randomized controlled study. Orthopade. 2019;48(3):239\u201347. https:\/\/doi.org\/10.1007\/s00132-018-03659-5.","journal-title":"Orthopade"},{"issue":"1","key":"6026_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1\u201312. https:\/\/doi.org\/10.1016\/0197-2456(95)00134-4.","journal-title":"Control Clin Trials"},{"issue":"10","key":"6026_CR28","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.joca.2020.07.003","volume":"28","author":"P Jayaram","year":"2020","unstructured":"Jayaram P, Liu C, Dawson B, et al. Leukocyte-dependent effects of platelet-rich plasma on cartilage loss and thermal hyperalgesia in a mouse model of post-traumatic osteoarthritis. Osteoarthritis Cartilage. 2020;28(10):1385\u201393. https:\/\/doi.org\/10.1016\/j.joca.2020.07.003.","journal-title":"Osteoarthritis Cartilage"},{"key":"6026_CR29","doi-asserted-by":"publisher","first-page":"138","DOI":"10.4103\/2277-9175.135156","volume":"3","author":"A Kabiri","year":"2014","unstructured":"Kabiri A, Esfandiari E, Esmaeili A, et al. Platelet-rich plasma application in chondrogenesis. Adv Biomed Res. 2014;3:138.","journal-title":"Adv Biomed Res"},{"issue":"2","key":"6026_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.46582\/jsrm.1202011","volume":"12","author":"JF Lana","year":"2016","unstructured":"Lana JF, Weglein A, Sampson SE, et al. Randomized controlled trial comparing hyaluronic acid, platelet-rich plasma and the combination of both in the treatment of mild and moderate osteoarthritis of the knee. J Stem Cells Regen Med. 2016;12(2):69\u201378. https:\/\/doi.org\/10.46582\/jsrm.1202011.","journal-title":"J Stem Cells Regen Med"},{"key":"6026_CR31","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1136\/bjsports-2014-094036","volume":"49","author":"ABM Laudy","year":"2015","unstructured":"Laudy ABM, Bakker EWP, Rekers M, et al. Efficacy of platelet-rich plasma injections in osteoarthritis of the knee: a systematic review and meta-analysis. Br J Sports Med. 2015;49:657\u201372.","journal-title":"Br J Sports Med"},{"issue":"1","key":"6026_CR33","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.arthro.2018.06.035","volume":"35","author":"KY Lin","year":"2019","unstructured":"Lin KY, Yang CC, Hsu CJ, Yeh ML, Renn JH. Intra-articular injection of platelet-rich plasma is superior to hyaluronic acid or saline solution in the treatment of mild to moderate knee osteoarthritis: a randomized, double-blind, triple-parallel, placebo-controlled clinical trial. Arthroscopy. 2019;35(1):106\u201317. https:\/\/doi.org\/10.1016\/j.arthro.2018.06.035.","journal-title":"Arthroscopy"},{"issue":"5","key":"6026_CR34","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/j.arthro.2017.11.035","volume":"34","author":"ML Louis","year":"2018","unstructured":"Louis ML, Magalon J, Jouve E, et al. Growth factors levels determine efficacy of platelet-rich plasma injection in knee osteoarthritis: a randomized double-blind noninferiority trial compared with viscosupplementation. Arthroscopy. 2018;34(5):1530\u2013e15402. https:\/\/doi.org\/10.1016\/j.arthro.2017.11.035.","journal-title":"Arthroscopy"},{"issue":"21","key":"6026_CR35","doi-asserted-by":"publisher","first-page":"7696","DOI":"10.1073\/pnas.84.21.7696","volume":"84","author":"SE Lynch","year":"1987","unstructured":"Lynch SE, Nixon JC, Colvin RB, Antoniades HN. Role of platelet-derived growth factor in wound healing: synergistic effects with other growth factors. Proc Natl Acad Sci U S A. 1987;84(21):7696\u2013700.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"6026_CR36","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.arthro.2014.02.020","volume":"30","author":"J Magalon","year":"2014","unstructured":"Magalon J, Bausset O, Serratrice N, et al. Characterization and comparison of 5 platelet-rich plasma preparations in a single-donor model. Arthroscopy. 2014;30(5):629\u201338. https:\/\/doi.org\/10.1016\/j.arthro.2014.02.020.","journal-title":"Arthroscopy"},{"issue":"9","key":"6026_CR37","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.joca.2016.04.018","volume":"24","author":"PS McCabe","year":"2016","unstructured":"McCabe PS, Maricar N, Parkes MJ, Felson DT, O\u2019Neill TW. The efficacy of intra-articular steroids in hip osteoarthritis: a systematic review. Osteoarthritis Cartilage. 2016;24(9):1509\u201317. https:\/\/doi.org\/10.1016\/j.joca.2016.04.018.","journal-title":"Osteoarthritis Cartilage"},{"issue":"3","key":"6026_CR38","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.joca.2017.11.014","volume":"26","author":"AE Nelson","year":"2018","unstructured":"Nelson AE. Osteoarthritis year in review 2017: clinical. Osteoarthritis Cartilage. 2018;26(3):319\u201325. https:\/\/doi.org\/10.1016\/j.joca.2017.11.014.","journal-title":"Osteoarthritis Cartilage"},{"issue":"7","key":"6026_CR40","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1177\/02692155221090407","volume":"36","author":"JC Nunes-Tamashiro","year":"2022","unstructured":"Nunes-Tamashiro JC, Natour J, Ramuth FM, et al. Intra-articular injection with platelet-rich plasma compared to triamcinolone Hexacetonide or saline solution in knee osteoarthritis: a double-blinded randomized controlled trial with one year follow-up. Clin Rehabil. 2022;36(7):900\u201315. https:\/\/doi.org\/10.1177\/02692155221090407.","journal-title":"Clin Rehabil"},{"issue":"1","key":"6026_CR41","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1152\/japplphysiol.00636.2005","volume":"101","author":"JL Olesen","year":"2006","unstructured":"Olesen JL, Heinemeier KM, Haddad F, et al. Expression of insulin-like growth factor I, insulin-like growth factor binding proteins, and collagen mRNA in mechanically loaded plantaris tendon. J Appl Physiol (1985). 2006;101(1):183\u20138.","journal-title":"J Appl Physiol (1985)"},{"issue":"2","key":"6026_CR42","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1177\/0363546520986867","volume":"49","author":"YB Park","year":"2021","unstructured":"Park YB, Kim JH, Ha CW, Lee DH. Clinical efficacy of platelet-rich plasma injection and its association with growth factors in the treatment of mild to moderate knee osteoarthritis: a randomized double-blind controlled clinical trial as compared with hyaluronic acid. Am J Sports Med. 2021;49(2):487\u201396. https:\/\/doi.org\/10.1177\/0363546520986867.","journal-title":"Am J Sports Med"},{"issue":"2","key":"6026_CR43","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1177\/0363546512471299","volume":"41","author":"S Patel","year":"2013","unstructured":"Patel S, Dhillon MS, Aggarwal S, et al. Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: a prospective, double-blind, randomized trial. Am J Sports Med. 2013;41(2):356\u201364. https:\/\/doi.org\/10.1177\/0363546512471299.","journal-title":"Am J Sports Med"},{"key":"6026_CR44","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.2147\/JPR.S210715","volume":"13","author":"SA Raeissadat","year":"2020","unstructured":"Raeissadat SA, Gharooee Ahangar A, Rayegani SM, et al. Platelet-rich plasma-derived growth factor vs hyaluronic acid injection in individuals with knee osteoarthritis: a one-year randomized clinical trial. J Pain Res. 2020;13:1699\u2013711. https:\/\/doi.org\/10.2147\/JPR.S210715.","journal-title":"J Pain Res"},{"issue":"1","key":"6026_CR45","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12891-021-04017-x","volume":"22","author":"SA Raeissadat","year":"2021","unstructured":"Raeissadat SA, Ghazi Hosseini P, Bahrami MH, et al. The comparison effects of intra-articular injection of platelet-rich plasma, plasma rich in growth factor, hyaluronic acid, and Ozone in knee osteoarthritis: a one-year randomized clinical trial. BMC Musculoskelet Disord. 2021;22(1):134. https:\/\/doi.org\/10.1186\/s12891-021-04017-x.","journal-title":"BMC Musculoskelet Disord"},{"key":"6026_CR46","doi-asserted-by":"publisher","first-page":"117954411773345","DOI":"10.1177\/1179544117733452","volume":"10","author":"SA Raeissadat","year":"2017","unstructured":"Raeissadat SA, Rayegani SM, Ahangar AG, et al. Efficacy of intra-articular injection of a newly developed plasma rich in growth factor (PRGF) versus hyaluronic acid on pain and function of patients with knee osteoarthritis: a single-blinded randomized clinical trial. Clin Med Insights Arthritis Musculoskelet Disord. 2017;10:1179544117733452. https:\/\/doi.org\/10.1177\/1179544117733452.","journal-title":"Clin Med Insights Arthritis Musculoskelet Disord"},{"issue":"11","key":"6026_CR47","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1093\/rheumatology\/kev228","volume":"54","author":"DG Remst","year":"2015","unstructured":"Remst DG, Davidson EB, Kraan PM. Unravelling osteoarthritis-related synovial fibrosis: a step closer to solving joint stiffness. Rheumatology (Oxford). 2015;54(11):1954\u201363. https:\/\/doi.org\/10.1093\/rheumatology\/kev228.","journal-title":"Rheumatology (Oxford)"},{"key":"6026_CR48","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","volume":"15","author":"G Rucker","year":"2015","unstructured":"Rucker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol. 2015;15:58. https:\/\/doi.org\/10.1186\/s12874-015-0060-8.","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"6026_CR49","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/PRS.0000000000008772","volume":"149","author":"OJ Smith","year":"2022","unstructured":"Smith OJ, Talaat S, Tomouk T, Jell G, Mosahebi A. An evaluation of the effect of activation methods on the release of growth factors from platelet-rich plasma. Plast Reconstr Surg. 2022;149(2):404\u201311. https:\/\/doi.org\/10.1097\/PRS.0000000000008772.","journal-title":"Plast Reconstr Surg"},{"issue":"5","key":"6026_CR50","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/PHM.0b013e3182aab72","volume":"91","author":"T Spakov\u00e1","year":"2012","unstructured":"Spakov\u00e1 T, Rosocha J, Lacko M, et al. Treatment of knee joint osteoarthritis with autologous platelet-rich plasma in comparison with hyaluronic acid. Am J Phys Med Rehabil. 2012;91(5):411\u20137. https:\/\/doi.org\/10.1097\/PHM.0b013e3182aab72.","journal-title":"Am J Phys Med Rehabil"},{"issue":"5","key":"6026_CR51","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s10067-018-3985-6","volume":"37","author":"K Su","year":"2018","unstructured":"Su K, Bai Y, Wang J, et al. Comparison of hyaluronic acid and PRP intra-articular injection with combined intra-articular and intraosseous PRP injections to treat patients with knee osteoarthritis. Clin Rheumatol. 2018;37(5):1341\u201350. https:\/\/doi.org\/10.1007\/s10067-018-3985-6.","journal-title":"Clin Rheumatol"},{"issue":"10","key":"6026_CR52","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1177\/0363546511417792","volume":"39","author":"EA Sundman","year":"2011","unstructured":"Sundman EA, Cole BJ, Fortier LA. Growth factor and catabolic cytokine concentrations are influenced by the cellular composition of platelet-rich plasma. Am J Sports Med. 2011;39(10):2135\u201340.","journal-title":"Am J Sports Med"},{"key":"6026_CR53","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1177\/0363546513507766","volume":"42","author":"EA Sundman","year":"2014","unstructured":"Sundman EA, Cole BJ, Karas V, et al. The anti-inflammatory and matrix restorative mechanisms of platelet-rich plasma in osteoarthritis. Am J Sports Med. 2014;42:35\u201341.","journal-title":"Am J Sports Med"},{"issue":"9","key":"6026_CR54","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1359\/jbmr.080409","volume":"23","author":"A Tokunaga","year":"2008","unstructured":"Tokunaga A, Oya T, Ishii Y, et al. PDGF receptor beta is a potent regulator of mesenchymal stromal cell function. J Bone Min Res. 2008;23(9):1519\u201328.","journal-title":"J Bone Min Res"},{"issue":"7","key":"6026_CR55","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/pmrj.12561","volume":"13","author":"JD Tucker","year":"2021","unstructured":"Tucker JD, Goetz LL, Duncan MB, et al. Randomized, placebo-controlled analysis of the knee synovial environment following platelet-rich plasma treatment for knee osteoarthritis. PM R. 2021;13(7):707\u201317. https:\/\/doi.org\/10.1002\/pmrj.12561.","journal-title":"PM R"},{"issue":"7","key":"6026_CR56","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.joca.2016.01.983","volume":"24","author":"M van Middelkoop","year":"2016","unstructured":"van Middelkoop M, Arden NK, Atchia I, et al. The OA trial bank: meta-analysis of individual patient data from knee and hip osteoarthritis trials show that patients with severe pain exhibit greater benefit from intra-articular glucocorticoids. Osteoarthritis Cartilage. 2016;24(7):1143\u201352. https:\/\/doi.org\/10.1016\/j.joca.2016.01.983.","journal-title":"Osteoarthritis Cartilage"},{"key":"6026_CR57","doi-asserted-by":"publisher","first-page":"812962","DOI":"10.3389\/fimmu.2022.812962","volume":"13","author":"DP Vasconcelos","year":"2022","unstructured":"Vasconcelos DP, Jabangwe C, Lamghari M, Alves CJ. The neuroimmune interplay in joint pain: the role of macrophages. Front Immunol. 2022;13:812962. https:\/\/doi.org\/10.3389\/fimmu.2022.812962.","journal-title":"Front Immunol"},{"issue":"1","key":"6026_CR58","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1053\/j.oto.2011.11.001","volume":"22","author":"AS Wasterlain","year":"2012","unstructured":"Wasterlain AS, Braun HJ, Dragoo JL. Contents and formulations of platelet-rich plasma. Oper Tech Orthop. 2012;22(1):33\u201342.","journal-title":"Oper Tech Orthop"},{"issue":"3","key":"6026_CR59","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1152\/physrev.2003.83.3.835","volume":"83","author":"S Werner","year":"2003","unstructured":"Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev. 2003;83(3):835\u201370.","journal-title":"Physiol Rev"},{"issue":"9","key":"6026_CR60","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1097\/JOM.0b013e3181715111","volume":"50","author":"AG White","year":"2008","unstructured":"White AG, Birnbaum HG, Janagap C, Buteau S, Schein J. Direct and indirect costs of pain therapy for osteoarthritis in an insured population in the united States. J Occup Environ Med. 2008;50(9):998\u20131005. https:\/\/doi.org\/10.1097\/JOM.0b013e3181715111.","journal-title":"J Occup Environ Med"},{"key":"6026_CR61","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jor.2020.01.041","volume":"20","author":"YU Yaradilmis","year":"2020","unstructured":"Yaradilmis YU, Demirkale I, Tagral SA, et al. Comparison of two platelet-rich plasma formulations with viscosupplementation in treatment of moderate-grade gonarthrosis: a prospective randomized controlled study. J Orthop. 2020;20:240\u20136. https:\/\/doi.org\/10.1016\/j.jor.2020.01.041.","journal-title":"J Orthop"},{"issue":"2","key":"6026_CR62","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/jor.22493","volume":"32","author":"R Yoshida","year":"2014","unstructured":"Yoshida R, Cheng M, Murray MM. Increasing platelet concentration in platelet-rich plasma inhibits anterior cruciate ligament cell function in three-dimensional culture. J Orthop Res. 2014;32(2):291\u20135.","journal-title":"J Orthop Res"}],"container-title":["Journal of Orthopaedic Surgery and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13018-025-06026-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13018-025-06026-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13018-025-06026-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T15:02:03Z","timestamp":1750777323000},"score":1,"resource":{"primary":{"URL":"https:\/\/josr-online.biomedcentral.com\/articles\/10.1186\/s13018-025-06026-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6026"],"URL":"https:\/\/doi.org\/10.1186\/s13018-025-06026-1","relation":{},"ISSN":["1749-799X"],"issn-type":[{"value":"1749-799X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]},"assertion":[{"value":"17 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"614"}}